首页 > 期刊论文 > 论文摘要
Progress in EIF5A2 gene in malignant tumors

摘    要
真核翻译起始因子5A2(eukaryotic translation initiation factor 5A2,EIF5A2)是EIF家族中一种保守的小分子量酸性蛋白质。研究发现,EIF5A2在肺癌、乳腺癌和宫颈癌等多种恶性肿瘤中过表达。EIF5A2主要通过诱导上皮-间质转化(epithelial-mesenchymal transition,EMT)促进肿瘤的发生和发展。N1-甲脒基-1,7-二氨基庚烷(N1-guanyl-1,7-diaminohep-tane,GC7)、环吡司(ciclopirox,CPX)和细胞活素类等药物的联合治疗,可干扰EIF5A2的翻译后修饰,进而抑制EIF5A2的活性,有望成为临床用药的不错选择。研究表明,EIF5A2作为一种致癌基因,可能成为肿瘤诊断和治疗中有效的分子生物学标志。本文就近年来EIF5A2在恶性肿瘤中的研究进展进行综述。
标    签 肿瘤   真核细胞起始因子类   上皮-间质转化   Neoplasms   Eukaryotic initiation factors   Epithelial-mesenchymal transition  
Eukaryotic translation initiation factor 5A2 (EIF5A2) is a small universally conserved acidic protein classified in the EIF family. It has been found that EIF5A2 is widely over-expressed in various carcinomas, such as lung cancer, breast cancer and cervical cancer. EIF5A2 mainly promotes the occurrence and development of carcinoma by inducing epithelial-mesenchymal transition. A combination therapy with N1-guanyl-1, 7-diaminohep-tane (GC7), ciclopirox (CPX) and cytokines pharmacological agents can inhibit the activity of EIF5A2 through interfering the process of hypusine post-translational modification, and it is expected to be a good choice for clinical medication. Studies have shown that EIF5A2, as a carcinogenic gene, may be an effective molecular biomarker in the diagnosis and treatment of cancer. This review summarizes the progress in EIF5A2 in carcinoma.

中图分类号 R730   DOI 10.3781/j.issn.1000-7431.2018.55.654

  购买该论文  中国光学期刊网论文下载说明

所属栏目 综述


收稿日期 2017/9/21

修改稿日期 2017/11/14



引用该论文: ZHOU Wu,WANG Junjie. Progress in EIF5A2 gene in malignant tumors[J]. Tumor, 2018, 38(3): 270~277
周婺,王俊杰. EIF5A2基因在恶性肿瘤中的研究进展[J]. 肿瘤, 2018, 38(3): 270~277

分享到新浪微博 分享到腾讯微博 分享到人人网 分享到 Google Reader 分享到百度搜藏分享到Twitter

【1】KEMPER WM, BERRY KW, MERRICK WC. Purification and properties of rabbit reticulocyte protein synthesis initiation factors M2Bα and M2Bβ[J]. J Biol Chem, 1976, 251(18):5551-5557.
【2】JACKSON RJ, HELLEN CU, PESTOVA TV. The mechanism of eukaryotic translation initiation an d principles of its regulation.[J]. Nat Rev Mol Cell Biol, 2010, 11(2):113-127.
【3】CARAGLIA M, PARK MH, WOLFF EC, et al. eIF5A isoforms and cancer:two brothers for two functions?[J]. Amino Acids, 2013, 44(1):103-109.
【4】WANG FW, GUAN XY, XIE D. Roles of eukaryotic initiation factor 5A2 in human cancer[J]. I Int J Biol Sci, 2013, 9(10):1013-1020.
【5】MÉMIN E, HOQUE M, JAIN MR, et al. Blocking eIF5A modification in cervical cancer cells alters the expression of cancer-related genes and suppresses cell proliferation[J]. Cancer Res, 2014, 74(2):552-562.
【6】RAMASWAMY S, ROSS KN, LANDER ES, et al. A molecular signature of metastasis in primary solid tumors[J]. Nat Genet, 2003, 33(1):49-54.
【7】LI Y, FU L, LI JB, et al. Increased expression of EIF5A2, via hypoxia or gene amplification, contributes to metastasis and angiogenesis of esophageal squamous cell carcinoma[J]. Gastroenterology, 2014, 146(7):1701-1713.
【8】HUANG PY, ZENG TT, BAN X, et al. Expression of EIF5A2 associates with poor survival of nasopharyngeal carcinoma patients treated with induction chemotherapy[J]. BMC Cancer, 2016, 16(1):1-9.
【9】HE LR, ZHAO HY, LI BK, et al. Overexpression of eIF5A-2 is an adverse prognostic marker of survival in stage I non-small cell lung cancer patients.[J]. Int J Cancer, 2011, 129(1):143-150.
【10】XU G, HUI Y, SHI X, et al. Cisplatin sensitivity is enhanced in non-small cell lung cancer cells by regulating epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2[J]. BMC Pulm Med, 2014, 14(1):174.
【11】LIU Y, DU F, CHEN W, et al. EIF5A2 is a novel chemoresistance gene in breast cancer[J]. Breast Cancer, 2015, 22(6):602-607.
【12】MENG QB, KANG WM, YU JC, et al. Overexpression of eukaryotic translation initiation factor 5A2(EIF5A2) correlates with cell aggressiveness and poor survival in gastric cancer[J]. PLos One, 2015, 10(3):e0119229.
【13】TANG DJ, DONG SS, MA NF, et al. Overexpression of eukaryotic initiation factor 5A2 enhances cell motility and promotes tumor metastasis in hepatocellular carcinoma[J]. Hepatology, 2010, 51(4):1255-1263.
【14】WANG FW, CAI MY, MAI SJ, et al. Ablation of EIF5A2 induces tumor vasculature remodeling and improves tumor response to chemotherapy via regulation of matrix metalloproteinase 2 expression[J]. Oncotarget, 2014, 5(16):6716-6733.
【15】ZHENG W, LI Z, NGUYEN AT, et al. Xmrk, Kras and Myc transgenic zebrafish liver cancer models share molecular signatures with subsets of human hepatocellular carcinoma[J]. PLoS One, 2014, 9(3):e91179.
【16】SHEK FH, FATIMA S, LEE NP. Implications of the use of eukaryotic translation initiation factor 5A (eIF5A) for prognosis and treatment of hepatocellular carcinoma[J]. Int J Hepatol, 2012, 2012(1):1-6.
【17】FUJIMURA K, WRIGHT T, STRNADEL J, et al. A hypusine-eIF5A-PEAK1 switch regulates the pathogenesis of pancreatic cancer[J]. Cancer Res, 2014, 74(22):6671-6681.
【18】WEI YX, CHEN G, YOU L, et al. Expression of eukaryotic translation initiation factor 5A2 in pancreatic adenocarcinoma and its correlation with the prognosis[J]. Zhongguo Yixue Kexueyuan Xuebao, 2013, 35(6):634-638.
【19】ZHU W, CAI MY, TONG ZT, et al. Overexpression of EIF5A2 promotes colorectal carcinoma cell aggressiveness by upregulating MTA1 through C-myc to induce epithelialmesenchymaltransition.[J]. Gut, 2012, 61(4):562-575.
【20】SNEZHKINA AV, KRASNOV GS, LIPATOVA AV, et al. The dysregulation of polyamine metabolism in colorectal cancer is associated with overexpression of c-Myc and C/EBPβ rather than enterotoxigenic bacteroides fragilis infection[J]. Oxid Med Cell Longev, 2016, 2016(3):1-11.
【21】DENG B, WANG B, FANG J, et al. MiRNA-203 suppresses cell proliferation, migration and invasion in colorectal cancer via targeting of EIF5A2[J]. Sci Rep, 2016, 6:28301.
【22】WEI JH, CAO JZ, ZHANG D, et al. EIF5A2 predicts outcome in localised invasive bladder cancer and promotes bladder cancer cell aggressiveness in vitro and in vivo[J]. Br J Cancer, 2014, 110(7):1767-1777.
【23】KHOSRAVI S, WONG RP, ARDEKANI GS, et al. Role of EIF5A2, a downstream target of Akt, in promoting melanoma cell invasion[J]. Br J Cancer, 2014, 110(2):399-408.
【24】YANG S, GAO Y, WANG D, et al. Overexpression of Eukaryotic initiation factor 5A2 is associated with cancer progression and poor prognosis in patients with early-stage cervical cancer[J]. Histopathology, 2016, 69(2):276-287.
【25】GUAN XY, FUNG JM, MA NF, et al. Oncogenic role of eIF-5A2 in the development of ovarian cancer[J]. Cancer Res, 2004, 64(12):4197-4200.
【26】ZIEGLER P, CHAHOUD T, WILHELM T, et al. Evaluation of deoxyhypusine synthase inhibitors targeting BCRABL positive leukemias[J]. Invest New Drugs, 2012, 30(6):2274-2283.
【27】PREUKSCHAS M, HAGEL C, SCHULTE A, et al. Expression of eukaryotic initiation factor 5A and hypusine forming enzymes in glioblastoma patient samples:implications for new targeted therapies[J]. PLos One, 2012, 7(8):e43468.
【28】LIU RR, LV YS, TANG YX, et al. Eukaryotic translation initiation factor 5A2 regulates the migration and invasion of hepatocellular carcinoma cells via pathways involving reactive oxygen species[J]. Oncotarget, 2016, 7(17):24348-24360.
【29】KHOSRAVI S, MARTINKA M, ZHOU Y, et al. Prognostic significance of the expression of nuclear eukaryotic translation initiation factor 5A2 in human melanoma[J]. Oncol Lett, 2016, 12(5):3089-3100.
【30】YANG H, LI X, ZHOU Y, et al. Stemness and chemotherapeutic drug resistance induced by EIF5A2 overexpression in esophageal squamous cell carcinoma[J]. Oncotarget, 2015, 6(28):26079-26089.
【31】ZHOU BF, WEI JH, CHEN ZH, et al. Identification and validation of AIB1 and EIF5A2 for noninvasive detection of bladder cancer in urine samples[J]. Oncotarget, 2016, 7(27):41703-41714.
【32】YANG J, YU H, SHEN M, et al. N1-guanyl-1, 7-diaminoheptane sensitizes bladder cancer cells to doxorubicin by preventing epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2 activation[J]. Cancer Sci, 2014, 105(2):219-227.
【33】MATHEWS MB, HERSHEY JW. The translation factor eIF5A and human cancer[J]. Biochim Biophys Acta, 2015, 1849(7):836-844.
【34】MURATA Y, MINAMI Y, IWAKAWA R, et al. ECT2 amplification and overexpression as a new prognostic biomarker for early-stage lung adenocarcinoma[J]. Cancer Sci, 2014, 105(4):490-497.
【35】LI L, LI W. Epithelial-mesenchymal transition in human cancer:comprehensive reprogramming of metabolism, epigenetics, and differentiation[J]. Pharmacol Ther, 2015, 150:33-46.
【36】GONZALEZ DM, MEDICI D. Signaling mechanisms of the epithelialmesenchymal transition[J]. Sci Signal, 2014, 7(344):re8.
【37】TIAN SB, YU JC, LIU YQ, et al. MiR-30b suppresses tumor migration and invasion by targeting EIF5A2 in gastric cancer[J]. World J Gastroenterol, 2015, 21(31):9337-9347.
【38】ZHANG W, FENG M, ZHENG G, et al. Chemoresistance to 5-fluorouracil induces epithelial-mesenchymal transition via up-regulation of Snail in MCF7 human breast cancer cells[J]. Biochem Biophys Res Commun, 2012, 417(2):679-685.
【39】MARCHINI S, FRUSCIO R, CLIVIO L, et al. Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer[J]. Eur J Cancer, 2013, 49(2):520-530.
【40】ZHENG L, QI T, YANG D, et al. microRNA-9 suppresses the proliferation, invasion and metastasis of gastric cancer cells through targeting cyclin D1 and Ets1[J]. PLoS One, 2013, 8(1):e55719.
【41】SONG YA, PARK YL, KIM KY, et al. RON is associated with tumor progression via the inhibition of apoptosis and cell cycle arrest in human gastric cancer[J]. Pathol Int, 2012, 62(2):127-136.
【42】YANG F, XUE X, BI J, et al. Long noncoding RNA CCAT1, which could be activated by c-Myc, promotes the progression of gastric carcinoma[J]. J Cancer Res Clin Oncol, 2013, 139(3):437-445.
【43】ISOSAKA M, NⅡNUMA T, NOJIMA M, et al. A screen for epigenetically silenced microRNA Genes in gastrointestinal stromal tumors[J]. PLoS One, 2015, 10(7):e0133754.
【44】ZENDER L, VILLANUEVA A, TOVAR V, et al. Cancer gene discovery in hepatocellular carcinoma[J]. J Hepatol, 2010, 52(6):921-929.
【45】XU X, ZHOU Y, XIE C, et al. Genomewide screening reveals an EMT molecular network mediated by sonic hedgehog-Gli1 signaling in pancreatic cancer cells[J]. PLoS One, 2012, 7(8):e43119.
【46】BAO Y, LU Y, WANG X, et al. Eukaryotic translation initiation factor 5A2(eIF5A2) regulates chemoresistance in colorectal cancer through epithelial mesenchymal transition[J]. Cancer Cell Int, 2015, 15(1):1-7.
【47】CHEN W, LUO JH, HUA WF, et al. Overexpression of EIF-5A2 is an independent predictr of outcome in patients of urothelial carcinoma of the bladder treated with radical cystectomy[J]. Cancer Epidemiol Biomarkers Prev, 2009, 18(2):400-408.
【48】XU G, SHAO G, PAN Q, et al. MicroRNA-9 regulates non-small cell lung cancer cell invasion and migration by targeting eukaryotic translation initiation factor 5A2[J]. Am J Transl Res, 2017, 9(2):478-488.
【49】WANG X, JIANG R, CUI EH, et al. N1-guanyl-1,7-diaminoheptane enhances the chemosensitivity of NSCLC cells to cetuximab through inhibition of eukaryotic translation initiation factor 5A2 activation[J]. Eur Rev Med Pharmacol Sci, 2016, 20(7):1244-1250.
【50】CARAGLIA M, MARRA M, GIUBERTI G, et al. The eukaryotic initiation factor 5A is involved in the regulation of proliferation and apoptosis induced by interferon-alpha and EGF in human cancer cells[J]. J Biochem, 2003, 133(6):757-765.
【51】LOU B, FAN J, WANG K, et al. N1-guanyl-1,7-diaminoheptane (GC7) enhances the therapeutic efficacy of doxorubicin by inhibiting activation of eukaryotic translation initiation factor 5A2(eIF5A2) and preventing the epithelial-mesenchymal transition in hepatocellular carcinoma cells[J]. Exp Cell Res, 2013, 319(17):2708-2717.
【52】FEI X, LIU Y, CHU H, et al. eIF5A2 is an alternative pathway for cell proliferation in cetuximabtreated epithelial hepatocellular carcinoma[J]. Am J Transl Res, 2016, 8(11):4670-4681.
【53】ROBEY RW, TO KK, POLGAR O, et al. ABCG2:a perspective[J]. Adv Drug Deliv Rev, 2009, 61(1):3-13.
   标题 相关频次
 SEPT 9基因与恶性肿瘤关系的研究进展
 18F-FDG PET/CT在同时性多原发癌中的应用


关于我们  |   联系我们  |   广告投放  |   《肿瘤》杂志社版权所有 《肿瘤》杂志社   © 中国 上海 2014.3